News Royalty Pharma plc

Equities

RPRX

GB00BMVP7Y09

Market Closed - Nasdaq Other stock markets 01:30:00 27/04/2024 am IST			5-day change	1st Jan Change
28 ^USD	-0.39%		-0.57%	-0.32%

09/04	Morgan Stanley Lifts Price Target on Royalty Pharma to $46 From $44, Keeps Overweight Rating	MT
05/03	Transcript : Royalty Pharma plc Presents at TD Cowen 44th Annual Health Care Conference 2024, Mar-05-2024 10:30 AM

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Fitch Affirms Royalty Pharma plc at 'BBB-'; Outlook Stable	22/04	AQ
Royalty Pharma to Announce First Quarter 2024 Financial Results on May 9, 2024	19/04	GL
Royalty Pharma Maintains Quarterly Dividend at $0.21 per Share, Payable June 14 to Shareholders of Record May 17	18/04	MT
Royalty Pharma Declares Second Quarter 2024 Dividend	17/04	GL
Royalty Pharma plc Declares Dividend for the Second Quarter of 2024, Payable on June 14, 2024	17/04	CI
Morgan Stanley Lifts Price Target on Royalty Pharma to $46 From $44, Keeps Overweight Rating	09/04	MT
Royalty Pharma : EEO-1 2023 Consolidated Report	03/04	PU
Royalty Pharma : TD Cowen Health Care Conference Transcript	08/03	PU
Transcript : Royalty Pharma plc Presents at TD Cowen 44th Annual Health Care Conference 2024, Mar-05-2024 10:30 AM	05/03
Royalty Pharma to Present at TD Cowen’s 44th Annual Health Care Conference	29/02	GL
Royalty Pharma to Present at TD Cowen’s 44th Annual Health Care Conference	29/02	AQ
JPMorgan Cuts Price Target on Royalty Pharma to $42 From $45, Keeps Overweight Rating	20/02	MT
Goldman Sachs Cuts Price Target on Royalty Pharma to $50 From $56, Keeps Buy Rating	20/02	MT
Tranche Update on Royalty Pharma plc's Equity Buyback Plan announced on March 28, 2023.	15/02	CI
Royalty Pharma plc Reports Earnings Results for the Full Year Ended December 31, 2023	15/02	CI
Royalty Pharma Swings to Q4 Net Income, Revenue Increases	15/02	MT
Royalty Pharma: Q4 Earnings Snapshot	15/02	AQ
Transcript : Royalty Pharma plc, Q4 2023 Earnings Call, Feb 15, 2024	15/02
Royalty Pharma plc Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	15/02	CI
Earnings Flash (RPRX) ROYALTY PHARMA Reports Q4 Revenue $596M, vs. Street Est of $674.5M	15/02	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Royalty Pharma plc

Equities

RPRX

GB00BMVP7Y09

Summary

Filters